FindTrial
Sign In

Prognosis Assessment Using Albumin–Bilirubin Grade for Patients with Hepatocellular Carcinoma Treated with Radiofrequency Ablation

Prognosis Assessment Using Albumin–Bilirubin Grade for Patients with Hepatocellular Carcinoma Treated with Radiofrequency Ablation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046280
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent hepatocellular carcinoma

Interventions

recurrent HCC after hepatectomy received RFA treatment group:No

Sponsors

Shandong Provincial Hospital affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age older than 18 years; 2. Diagnosis of intrahepatic recurrent HCC after initial curative hepatic resection; 3. No evidence of macroscopic vascular invasion or extrahepatic metastasis; 4. Up to 3 tumor nodules with each nodule <= 5 cm; 5. Child-Pugh class A or B; 6. No cardiopulmonary, renal or cerebral dysfunction.

Exclusion criteria

Exclusion criteria: 1.Laparoscopic RFA or intraoperative RFA; 2.Patients with other untreated malignancies or other serious concurrent illnesses.

Design outcomes

Primary

MeasureTime frame
overall survival;liver function;—

Countries

China

Contacts

Public ContactZhu Qiang

Shandong Provincial Hospital affiliated to Shandong First Medical University

zhuqiang@sdu.edu.cn+86 15168887780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026